Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. Among authors: cobo m. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators. Ahn MJ, et al. Among authors: cobo m. J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9. J Clin Oncol. 2025. PMID: 39250535 Free PMC article. Clinical Trial.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Among authors: cobo m. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
First year after surgery is the optimal period to define early prosthetic valve endocarditis: a cohort study.
Calderón-Parra J, Escrihuela F, Cuervo G, López-Azor JC, Muñoz P, Machado M, Marín M, Rodríguez-Esteban MÁ, Rodríguez-García R, Gutiérrez F, Miró Meda JM, Goenaga MÁ, Goikoetxea-Agirre J, de Alarcón A, Vidal-Bonnet L, Ramos-Martinez A; GAMES Investigators. Calderón-Parra J, et al. Open Heart. 2025 Jun 26;12(1):e003378. doi: 10.1136/openhrt-2025-003378. Open Heart. 2025. PMID: 40571490 Free article.
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.
Carbone DP, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Felip E, Cheng Y, Juan-Vidal O, Alexandru A, Mizutani H, Reinmuth N, Lu S, Reck M, John T, Scherpereel A, De Marchi P, Aoyama T, Sathyanarayana P, Grootendorst DJ, Hu N, Ip V, Hung YH, Paz-Ares LG. Carbone DP, et al. Among authors: cobo m. ESMO Open. 2025 Jun;10(6):105123. doi: 10.1016/j.esmoop.2025.105123. Epub 2025 May 29. ESMO Open. 2025. PMID: 40446626 Free PMC article. Clinical Trial.
Pain in women: bridging the gender pain gap.
Laughey W, Vincent K, Iyer S, Cobo MM, Slater R. Laughey W, et al. Among authors: cobo mm. Pain Rep. 2025 May 20;10(3):e1276. doi: 10.1097/PR9.0000000000001276. eCollection 2025 Jun. Pain Rep. 2025. PMID: 40401085 Free PMC article.
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M, Teixidó C, Álvarez-Fernández C, Arasanz H, Peralta S, Lázaro M, Calvo V, Álvarez R, Baena J, Valdivia J, Arriola E, Bernabé R, Isla D, Camacho C, Massutí B, Blasco A, García T, Cobo M, Campayo M, Hijazo-Pechero S, Callejo Á, Domínguez M, Nadal E. Varela M, et al. Among authors: cobo m. Transl Lung Cancer Res. 2025 Apr 30;14(4):1254-1265. doi: 10.21037/tlcr-2024-1146. Epub 2025 Apr 21. Transl Lung Cancer Res. 2025. PMID: 40386732 Free PMC article.
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.
Serna-Blasco R, Mediavilla-Medel P, Medina K, Sala MÁ, Aguiar D, Díaz-Serrano A, Antoñanzas M, Ocaña J, Mielgo X, Fernández I, López-Castro R, Cobo M, Martínez M, Villa JC, Rosado P, López A, Guirado M, Viteri S, Rodríguez D, García F, Simón S, Moreno MÁ, Catot S, González Larriba JL, Salas C, Calvo V, Romero A, Provencio M. Serna-Blasco R, et al. Among authors: cobo m. Lung Cancer. 2025 Jun;204:108550. doi: 10.1016/j.lungcan.2025.108550. Epub 2025 Apr 24. Lung Cancer. 2025. PMID: 40300279 Free article.
399 results